Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL2231852 | 0.98 | LDHA (0.38) | LDHASRRCYP2C19 | |
| Metformin SCHEMBL1557197 | 0.88 | GLRA1 (0.40) | CYP2C19 | |
| Metformin SCHEMBL1558869 | 0.88 | PHF8 (0.41) | CYP2C19 | |
| Metformin SCHEMBL991100 | 0.88 | FFAR3 (0.40) | CYP2C19 | |
| Metformin SCHEMBL7647374 | 0.88 | PHF8 (0.41) | CYP2C19 | |
| Metformin SCHEMBL28844380 | 0.88 | — | — | |
| Metformin SCHEMBL7123890 | 0.86 | PHF8 (0.39) | — | |
| Metformin SCHEMBL4364474 | 0.85 | LMNA (0.30) | — | |
| Metformin SCHEMBL1323029 | 0.85 | CRBN (0.33) | — | |
| Metformin SCHEMBL4410446 | 0.85 | CRBN (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203418-B1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2017-10-25 | — | — | EP | disclosed |
| CN-101855204-B | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL BIOPHARMA CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-8076377-B2 | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2011-12-13 | — | — | US | disclosed |
| CN-101855204-A | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same | HANALL PHARMACEUTICAL COMPANY LTD | 2010-10-06 | — | — | CN | disclosed |
| US-20100249241-A1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY, LTD. (KR) | 2010-09-30 | — | — | US | disclosed |
| EP-2203418-A2 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038396-A2 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249241-A1 | N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | TNNC1, TP53, CAD | LDHA 293/4885SRR 3453/4885CYP2C19 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.